Protagenic Therapeutics achieves milestone in Phase I trial for PT00114, a compound for treating stress-related neuro-psychiatric disorders. No adverse reactions ...
US defense company Leidos Holdings Inc sets an ambitious full-year profit target that surpasses expectations amid high geopolitical tensions, benefiting ...